

# Funded vaccines for special groups from 1st July 2017

Please refer to individual vaccines on the following pages for detailed eligibility criteria and to the *Immunisation Handbook 2017* for vaccine administration schedules

<b>Asplenia – Functional or Pre- or Post-Splenectomy Immunisation Programme</b> <ul style="list-style-type: none"> <li>Hib, influenza, meningococcal, pneumococcal, and Tdap vaccines</li> </ul>	<b>Influenza Immunisation Programme</b> <ul style="list-style-type: none"> <li>Pregnancy,</li> <li>Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness,</li> <li>Individuals aged 6 months to under 65 years with an eligible medical condition,</li> <li>Individuals aged 65 years or older,</li> <li>Individuals aged under 18 years living in specified earthquake or flood affected areas in Bay of Plenty, Nelson Marlborough or Canterbury District Health Boards.</li> </ul>
<b>Chemotherapy – following</b> <ul style="list-style-type: none"> <li>Hib, HPV, influenza, pneumococcal, Tdap, and varicella vaccines</li> </ul> <b>Also consider immunosuppression for longer than 28 days</b> <ul style="list-style-type: none"> <li>Hepatitis B and meningococcal vaccines</li> </ul>	<ul style="list-style-type: none"> <li>Influenza vaccine</li> </ul>
<b>Cochlear implant</b> <ul style="list-style-type: none"> <li>Hib, influenza, and pneumococcal vaccines</li> </ul>	<b>Kidney disease</b> <ul style="list-style-type: none"> <li>Hepatitis B, Hib, influenza, pneumococcal, Tdap, and varicella vaccines</li> </ul>
<b>Error of metabolism at risk of major metabolic decompensation</b> <ul style="list-style-type: none"> <li>Influenza and varicella vaccines</li> </ul>	<b>Liver disease</b> <ul style="list-style-type: none"> <li>Hepatitis A and varicella vaccines</li> </ul>
<b>Haematopoietic stem cell transplantation (HSCT) – following</b> <ul style="list-style-type: none"> <li>Hib, HPV, influenza, meningococcal, pneumococcal, Tdap, and varicella vaccines</li> </ul> <b>Also consider immunosuppression for longer than 28 days</b> <ul style="list-style-type: none"> <li>Hepatitis B vaccine</li> </ul>	<b>Meningococcal disease case – contact with</b> <ul style="list-style-type: none"> <li>Meningococcal vaccine</li> </ul>
<b>Hepatitis A case – contact with</b> <ul style="list-style-type: none"> <li>Hepatitis A vaccine</li> </ul>	<b>Needle stick injury – following</b> <ul style="list-style-type: none"> <li>Hepatitis B vaccine</li> </ul>
<b>Hepatitis B case – contact with</b> <p><b>Infants born to mothers who are hepatitis B surface antigen (HBsAg) positive</b></p> <ul style="list-style-type: none"> <li>Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) at birth</li> </ul> <p><b>Household and sexual contacts of known acute hepatitis B cases or carriers</b></p> <ul style="list-style-type: none"> <li>Hepatitis B vaccine</li> </ul>	<b>Non-consensual sexual intercourse – following</b> <ul style="list-style-type: none"> <li>Hepatitis B vaccine</li> </ul>
<b>Hepatitis C positive individual</b> <ul style="list-style-type: none"> <li>Hepatitis B vaccine</li> </ul>	<b>Pneumococcal disease – increased risk</b> <ul style="list-style-type: none"> <li>Additional pneumococcal vaccines</li> </ul>
<b>HIV positive individual</b> <ul style="list-style-type: none"> <li>Hepatitis B, HPV, influenza, meningococcal, pneumococcal, and varicella vaccines</li> </ul>	<b>Pregnancy</b> <ul style="list-style-type: none"> <li>Influenza and Tdap vaccines in every pregnancy</li> </ul>
<b>Immune deficiency/immunosuppression</b> <p><b>Individuals with an immune deficiency</b></p> <ul style="list-style-type: none"> <li>Influenza, meningococcal, and pneumococcal vaccines</li> </ul> <p><b>Household contacts of children or adults who will be/are immunosuppressed</b></p> <ul style="list-style-type: none"> <li>Varicella vaccine</li> </ul> <p><b>Prior to elective immunosuppression for longer than 28 days</b></p> <ul style="list-style-type: none"> <li>Varicella vaccine</li> </ul> <p><b>Following immunosuppression for longer than 28 days</b></p> <ul style="list-style-type: none"> <li>Hepatitis B, Hib, influenza, meningococcal, and Tdap vaccines</li> </ul>	<b>Rubella – women of childbearing age who are not immune to rubella</b> <ul style="list-style-type: none"> <li>MMR vaccine</li> </ul>
	<b>Solid organ transplantation</b> <p><b>Prior to solid organ transplantation</b></p> <ul style="list-style-type: none"> <li>Hib, meningococcal, pneumococcal, Tdap, and varicella vaccines</li> </ul> <p><b>Following solid organ transplantation</b></p> <ul style="list-style-type: none"> <li>Hepatitis A, hepatitis B, Hib, HPV, influenza, meningococcal, pneumococcal, and Tdap vaccines</li> </ul>
	<b>Tuberculosis – infants and children aged under 5 years at risk of tuberculosis (TB) exposure</b> <ul style="list-style-type: none"> <li>BCG vaccine</li> </ul>

**Vaccine key – BCG:** tuberculosis; **Hib:** *Haemophilus influenzae* type b; **HPV:** human papillomavirus; **MMR:** measles, mumps, rubella; **Tdap:** tetanus, diphtheria, acellular pertussis; **varicella:** chickenpox.

# Funded vaccines for special groups from 1st July 2017

Vaccine	Individuals eligible for funded vaccine
<i>Haemophilus influenzae</i> type b (Hib) vaccine (Chapter 6 <sup>#</sup> )	<ul style="list-style-type: none"> <li>An additional dose (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; pre- or post-cochlear implant; with functional asplenia; on renal dialysis or a severely immunosuppressive regimen</li> </ul>
Hepatitis A vaccine (Chapter 7 <sup>#</sup> )	<ul style="list-style-type: none"> <li>One dose for close contacts of a hepatitis A case</li> <li>Two doses for transplant patients; or children with chronic liver disease</li> </ul>
Hepatitis B vaccine or Hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) (Chapter 8 <sup>#</sup> )	<ul style="list-style-type: none"> <li>Infants born to a mother who is hepatitis B surface antigen (HBsAg) positive; household or sexual contacts of a known acute hepatitis B case or hepatitis B carrier; individuals who are HIV-positive; hepatitis C positive; solid organ transplant patients (excluding liver or kidney, refer below); following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days*; non-consensual sexual intercourse; or needle stick injury (5mcg/0.5mL or 10mcg/1.0mL as appropriate)</li> <li>Children under the age of 18 years who are considered not to have achieved a positive serology and require additional vaccination (5mcg/0.5mL or 10mcg/1.0mL as appropriate)</li> <li>Adults who are on renal dialysis; or who are liver or kidney transplant patients (40mcg/1.0mL)</li> </ul>
Human papillomavirus (HPV) vaccine (Chapter 9 <sup>#</sup> )	<ul style="list-style-type: none"> <li>Three doses for individuals aged 9–26 years inclusively post-solid organ transplantation; post-haematopoietic stem cell transplantation; or who are HIV-positive</li> <li>A maximum of four doses for people aged 9–26 years inclusively post-chemotherapy</li> </ul>
Influenza vaccine (Chapter 10 <sup>#</sup> and the Influenza Kit)	<ul style="list-style-type: none"> <li>Pregnant women in every pregnancy during vaccination season</li> <li>Children aged 6 months to under 5 years who have been hospitalised for respiratory illness or have a history of significant respiratory illness</li> <li>Individuals aged 65 years and older</li> <li>Individuals aged 6 months to under 65 years with certain medical conditions, as per the Influenza Kit, including individuals pre- or post-splenectomy; or with Down syndrome, cochlear implant, error of metabolism at risk of major metabolic decompensation</li> <li><b>UPDATED</b> Individuals aged under 18 years living in the Seddon/Ward and rural Eastern Marlborough region (within the Nelson Marlborough District Health Board) and Kaikoura and Hurunui areas (within the Canterbury District Health Board); or who have been displaced from their homes in Edgecumbe and the surrounding region (Bay of plenty District Health Board)</li> </ul>
Meningococcal conjugate vaccines (MenCCV under 2 years and MCV4-D 2 years or older) (Chapter 12 <sup>#</sup> )	<ul style="list-style-type: none"> <li>One dose for a close contacts of meningococcal disease case</li> <li>Two doses for individuals post-haematopoietic stem cell transplantation; or following immunosuppression due to steroid or other immunosuppressive therapy longer than 28 days*</li> <li>Up to three doses plus booster doses (as appropriate) for individuals pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; complement deficiency (acquired or inherited); or who are HIV-positive</li> </ul>
Tetanus, diphtheria and pertussis (Tdap) vaccine (Chapter 14 <sup>#</sup> )	<ul style="list-style-type: none"> <li>One dose for pregnant women, between gestational weeks 28 and 38 of every pregnancy</li> <li>Up to four additional doses (as appropriate) for (re-)immunisation of individuals post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; on renal dialysis or a severely immunosuppressive regimen</li> </ul>

<sup>#</sup> Refer to recommended chapter in the Immunisation Handbook 2017.

\* For example chemotherapy regimens to treat cancer, conditioning regimes prior to haematopoietic stem cell transplantation, and treatment of immune mediated inflammatory disease.

# Funded vaccines for special groups from 1st July 2017

Vaccine	Individuals eligible for funded vaccine
Pneumococcal conjugate (PCV13) and pneumococcal polysaccharide (23PPV) vaccines (Chapter 15 <sup>#</sup> )	<p><b>Children aged under 5 years</b> <b>UPDATED</b></p> <p>Cardiac disease with cyanosis or failure; cerebrospinal fluid leak; chronic pulmonary disease, including asthma treated with high-dose corticosteroid therapy; cochlear implant; corticosteroid therapy for more than two weeks and who are on an equivalent daily dosage of prednisone of 2 mg/kg per day or greater, or children who weigh more than 10 kg on a total daily dosage of 20 mg or greater; diabetes; Down syndrome; functional asplenia; HIV-positive; immunosuppressive therapy; intracranial shunt; nephrotic syndrome; pre- or post-splenectomy; pre-term infant born before 28 weeks gestation; primary immune deficiency; post-haematopoietic stem cell transplantation; post-solid organ transplantation; radiation therapy; or renal failure</p> <p><b>Children aged 5 years or older, and adults</b> <b>UPDATED</b></p> <p>Post-haematopoietic stem cell transplantation; post-chemotherapy; pre- or post-splenectomy; pre- or post-solid organ transplantation; with functional asplenia; cochlear implant; complement deficiency (acquired or inherited); primary immunodeficiency; on renal dialysis or who are HIV-positive</p>
	<p>PCV13:</p> <ul style="list-style-type: none"> <li>• One dose for children aged 18 months to under 18 years who have previously received four doses of PCV10, or</li> <li>• Up to an additional four doses (as appropriate) for (re-)immunisation of children and adults</li> </ul>
	<p>23PPV:</p> <ul style="list-style-type: none"> <li>• Up to two doses (as appropriate) for children aged 2 years to under 18 years receiving 23PPV vaccine for the first time, or</li> <li>• Up to three doses (as appropriate) for individuals aged 18 years or older receiving 23PPV vaccine for the first time</li> </ul>
BCG vaccine (Bacillus Calmette-Guérin) (Chapter 20 <sup>#</sup> )	All public health community BCG Vaccination Clinics and in-hospital vaccinations are postponed until further notice, due to a global shortage of BCG vaccine.
Varicella vaccine (Chapter 21 <sup>#</sup> )	<p>Two doses for non-immune individuals:</p> <ul style="list-style-type: none"> <li>• Who are HIV-positive with mild or moderate immunosuppression, on the advice of their specialist</li> <li>• Prior to elective immunosuppressive therapy that will be longer than 28 days<sup>Ψ</sup></li> <li>• With chronic liver disease who may in future be candidates for transplantation</li> <li>• With deteriorating renal function before transplantation</li> <li>• Pre-solid organ transplantation</li> <li>• Post-haematopoietic stem cell transplantation, on the advice of their specialist</li> <li>• Post-chemotherapy, on the advice of their specialist</li> <li>• Who are immune competent inpatients exposed to varicella, for post-exposure prophylaxis</li> </ul> <p>Two doses for individuals with no clinical history of varicella infection or immunisation:</p> <ul style="list-style-type: none"> <li>• With an inborn error of metabolism at risk of major metabolic decompensation</li> <li>• Who are a household contact of a paediatric patient who is immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation</li> <li>• Who are a household contact of an adult patient who has no clinical history of varicella and who is severely immunocompromised or undergoing a procedure leading to immune compromise, where the household contact has no clinical history of varicella infection or immunisation</li> </ul>

<sup>#</sup> Refer to recommended chapter in the Immunisation Handbook 2017.

<sup>Ψ</sup> For example treatment of immune mediated inflammatory disease.